Industry Experts Share Insights on MGI’s Latest Sequencing Innovations at ICG-14
Recently, at the 14th International Genomics Conference (ICG-14) held in Shenzhen, MGI’s new product launch drew wide attention from the genomics industry. Following the event, experts from both academia and industry shared their perspectives through interviews and discussions.
Promoting Genomics Technology and Applications
Dr. Gang Gang, Founder and CEO of WeGene: “In previous ICGs, the focus was largely academic. This year, seeing many industry participants highlights that genomics technology and applications are increasingly reaching both industry and users. At WeGene, we aim to make personal genomes relevant to everyday life, helping individuals better manage health and prevent disease. As technology advances and user data grows, our predictive and analytical capabilities become more precise, enabling targeted interventions for healthier, longer lives.”
“MGI has developed rapidly—from BGISEQ-500 to DNBSEQ-G400 and now the ultra-high-throughput DNBSEQ-T7. WeGene is among the first users of DNBSEQ-T7 and has generated our first whole genome sequencing data. We anticipate MGI will expand into more omics and phenotype detection devices, fostering partnerships and collaborative development.”
Consistent Partnership with MGI
Charmian Cher, Director of Clinical Strategy APAC, Agilent Technologies: “Agilent has a long-standing partnership with MGI. Their rapid development in sequencing and broad platform applications align with our experience in target enrichment and precision medicine. Sequencing is becoming faster, cheaper, and increasingly clinical. Our framework agreement with MGI aims to bring more accessible, accurate, and comprehensive packages to clinical research.”
Proven Compatibility with Roche Reagents
Yan Yiwen, Senior Science Value Manager, Roche Diagnostics: “Roche’s general-purpose reagents perform excellently on MGI sequencers. With MGI releasing new products yearly—from the ultra-high-throughput DNBSEQ-T7 to the portable DNBSEQ E series—the potential for collaboration in clinical disease, oncology, and hereditary disorders is significant.”
Addressing Data Analysis Challenges
Li Qibin, PhD, Clabee Genomics: “High-throughput sequencing is increasingly convenient, but clinical data analysis remains challenging, requiring high-performance computing and professional bioinformatics expertise. We partnered with MGI to develop a genetic data analysis and interpretation machine, combining MGI’s Megabolt bioinformatics acceleration package with Clabee Genomics’ Seqmax platform to support clinical genetic diagnostics. The new MGI products at ICG show promise for broader adoption in research institutions and hospitals.”
Compact, Powerful Single-Cell Processing
Tian Geng, CEO, Geneis: “My career started at BGI, and genomics has been a major part of my life. At this year’s ICG, the new portable single-cell processing device impressed me. Weighing just 200 grams, it requires no professional test bench or lab yet delivers powerful single-cell preparation. The DNBSEQ-G400 has provided high-quality data, and I look forward to shorter run times and improved industrial design.”
Supporting Domestic Sequencing Platforms
Xue Yaxin, Marketing Director, Nanodigmbio Technology: “We partnered with MGI to provide complete library preparation and target enrichment packages for the DNBSEQ platform, ensuring users receive high-quality application support. Our work includes exome capture, pan-cancer capture, and circulating tumor DNA applications. DNBSEQ’s data quality and stability are excellent, and we are confident in continued collaboration.”
Future Directions
Experts agreed that genomics technology will develop toward being broader, more accurate, and more refined: covering a wider population, increasing sequencing precision and sensitivity, and refining application segmentation. MGI’s ongoing innovation in sequencing platforms, single-cell preparation, and data analysis is expected to accelerate clinical and research applications, driving the future of precision medicine.
